EP0062

EP0062 or Vosilasarm[1] is a selective androgen receptor modulator under development by Ellipses Pharma for the treatment of AR+/HER2-/ER+ advanced breast cancer.[2][3]

References
  1. "Our Portfolio | Ellipses Pharma". Ellipses Life. Retrieved 11 October 2023.
  2. Lim, Elgene; Hamilton, Erika; Palmieri, Carlo; Arkenau, Hendrik-Tobias; Brook, Sue; Fisher, Geoff; Mazur, Andrew (1 March 2023). "Abstract OT1-02-02: A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer". Cancer Research. 83 (5_Supplement): OT1–02–02-OT1-02-02. doi:10.1158/1538-7445.SABCS22-OT1-02-02.
  3. "Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 26 September 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.